CTIS2024-510576-21-00进行中（未招募）1 期
Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial - PERFUPANC-001
Catharina Ziekenhuis Stichting0 个研究点目标入组 100 人开始时间: 2024年4月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Pathologically confirmed pancreatic cancer diagnosis (for PART B: unresectable locally advanced or metastatic setting), Patient scheduled to start FOLFIRINOX treatment, Patient with age = 18, Patient is able and willing to give written IFC, Patient is able and willing to undergo extra blood sampling for 5-FU analysis, WHO performance status 0-2
排除标准
- •Patient with known substance abuse, psychotic disorders, and/or other diseases expected to interfere with study or patient’s safety, Patient with DPYD gene-activity score 0 and 0.5
研究者
相似试验
Unknown
1 期
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic CancerPancreatic CancerNCT03989310Chinese PLA General Hospital50
进行中（未招募）
2 期
MFOLFIRINOX with or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic AdenocarcinomaPancreatic AdenocarcinomaPancreatic Cancer Non-resectableNCT04986930Asan Medical Center92
Unknown
2 期
Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic CancerPancreatic CancerNCT05399394Campus Bio-Medico University50
终止
2 期
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II StudyPancreatic AdenocarcinomaPoorly Differentiated Malignant NeoplasmResectable Pancreatic CancerStage IA Pancreatic CancerStage IB Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic CancerStage III Pancreatic CancerUndifferentiated Pancreatic CarcinomaNCT02345460Case Comprehensive Cancer Center1
招募中
不适用
Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastimnresectable pancreatic cancerJPRN-UMIN000028055Kanazawa University Hospital33